JIR
ACOR

James Investment Research’s Acorda Therapeutics ACOR Stock Holding History

James Investment Research’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-302
Closed -$278K – 666
2019
Q2 		$278K Sell
302
-34
-10% -$41.8K 0.02% 287
2019
Q1 		$535K Buy
336
+100
+42% +$180K 0.03% 446
2018
Q4 		$441K Sell
236
-815
-78% -$1.77M 0.03% 467
2018
Q3 		$2.48M Buy
+1,051
New +$3.25M 0.1% 194

Other funds holding ACOR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
SCM
Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

James Investment Research's ACOR Position: Q3 2019 in Review

James Investment Research sold out of Acorda Therapeutics (ACOR) in Q3 2019, closing a stake of 302 shares — an estimated $278K sold.

James Investment Research first reported a position in ACOR in Q3 2018 and held it in 4 quarters. The position peaked at $2.48M in Q3 2018. 151 funds tracked by Wall St. Rank hold ACOR as of Q3 2019.

  • James Investment Research reported no remaining Acorda Therapeutics position as of Q3 2019 after selling out during the quarter.
  • James Investment Research sold 302 Acorda Therapeutics shares in Q3 2019, an estimated $278K.
  • James Investment Research first reported a position in Acorda Therapeutics in Q3 2018 and held it in 4 quarters.
  • James Investment Research's Acorda Therapeutics position peaked at $2.48M in Q3 2018.
  • 151 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q3 2019.

Based on James Investment Research's 13F filing for Q3 2019, filed 30 Oct 2019.